Biogen's Alzheimer's disease sales are negative as Aduhelm fallout lingers
Aduhelm continues to haunt Biogen, causing $18M Alzheimer's hit
https://www.fiercepharma.com/pharma...llion-alzheimers-loss-aduhelm-fallout-lingers
You’ve got to spend money to make money, and for Biogen, that means an $18 million revenue hit attributable to the company's Alzheimer's portfolio.
As the drugmaker holds out hope for broader coverage of its Eisai-partnered Alzheimer’s med Leqembi, the amyloid antibody’s controversial predecessor, Aduhelm, continues to weigh on the company's financials. During the first quarter, Aduhelm write-downs spurred an $18 million revenue hit from the neurodegenerative disease category.
Biogen’s negative Alzheimer's revenue accounts for sales of both Aduhelm and Leqembi, the company explained in a press release Tuesday. Since Leqembi just reached the market and Aduhelm is still costing the company hundreds of millions of dollars, the two approved treatments are actually dragging on companywide financials.
Aduhelm continues to haunt Biogen, causing $18M Alzheimer's hit
https://www.fiercepharma.com/pharma...llion-alzheimers-loss-aduhelm-fallout-lingers
You’ve got to spend money to make money, and for Biogen, that means an $18 million revenue hit attributable to the company's Alzheimer's portfolio.
As the drugmaker holds out hope for broader coverage of its Eisai-partnered Alzheimer’s med Leqembi, the amyloid antibody’s controversial predecessor, Aduhelm, continues to weigh on the company's financials. During the first quarter, Aduhelm write-downs spurred an $18 million revenue hit from the neurodegenerative disease category.
Biogen’s negative Alzheimer's revenue accounts for sales of both Aduhelm and Leqembi, the company explained in a press release Tuesday. Since Leqembi just reached the market and Aduhelm is still costing the company hundreds of millions of dollars, the two approved treatments are actually dragging on companywide financials.